Innate Pharma S.A.
IPHA
$2.07
$0.041.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -50.09M | -51.31M | -53.52M | -45.35M | -36.82M |
| Total Depreciation and Amortization | 1.70M | 1.91M | 2.16M | 2.48M | 2.80M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.46M | 3.42M | 1.54M | 979.30K | 401.50K |
| Change in Net Operating Assets | -1.90M | 20.46M | 42.35M | 28.36M | 14.07M |
| Cash from Operations | -44.84M | -25.52M | -7.47M | -13.53M | -19.55M |
| Capital Expenditure | -180.40K | -299.80K | -422.90K | -387.90K | -351.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 80.70K | 162.30K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 16.76M | 13.42M | 10.38M | 17.10M | 23.79M |
| Cash from Investing | 16.58M | 13.12M | 9.96M | 16.79M | 23.61M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.97M | -8.95M | -8.94M | -7.06M | -5.19M |
| Issuance of Common Stock | 17.77M | 10.35M | 2.93M | 1.53M | 140.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9.64M | 1.36M | -6.50M | -5.99M | -5.46M |
| Foreign Exchange rate Adjustments | 849.10K | 130.90K | -546.30K | -344.70K | -138.20K |
| Miscellaneous Cash Flow Adjustments | -1.10K | -1.10K | -1.10K | -600.00 | 0.00 |
| Net Change in Cash | -17.77M | -10.90M | -4.56M | -3.08M | -1.54M |